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Abstract
Background: We investigated the neuroprotective properties of levosimendan, a novel inodilator, in an in vitro
model of traumatic brain injury.
Methods: Organotypic hippocampal brain slices from mouse pups were subjected to a focal mechanical trauma.
Slices were treated after the injury with three different concentrations of levosimendan (0.001, 0.01 and 0.1 μM)
and compared to vehicle-treated slices. After 72 hrs, the trauma was quantified using propidium iodide to mark
the injured cells.
Results: A significant dose-dependent reduction of both total and secondary tissue injury was observed in cells
treated with either 0.01 or 0.1 μM levosimendan compared to vehicle-treated slices.
Conclusion: Levosimendan represents a promising new pharmacological tool for neuroprotection after brain injury
and warrants further investigation in an in vivo model.
Background
Traumatic brain injury (TBI) is common, carries high
rates of morbidity and mortality and lacks specific treat-
ment. In our study of TBI, the initial lesion results from
direct mechanical damage at the impact site. Subse-
quently, several cellular and molecular processes expand
the local injury. This so-called secondary injury is due
to several factors: excitotoxicity; mitochondrial dysfunc-
tion resulting in the up-regulation of cell-death genes
and the formation of free radicals; and proapoptotic
mediator pathway activation [1]. At present, medical
intervention cannot rescue directly traumatised, dying
cells. Therefore, current neuroprotective drugs target
the surviving cells near the impact site [2]. Hypotension,
hypoxia, hyper- and hypocapnia, and hyper- and hypo-
glycemia remain potentially avoidable insults, all of
which aggravate the outcomes of TBI [3]. Levosimendan
is a novel inodilator that enhances myocardial perfor-
mance without leading to substantial changes in oxygen
consumption. Levosimendan’s positive inotropic and
vasodilator effects are tied to its abilities to increase
calcium sensitivity and open ATP-sensitive K+ channels
(mitoKATPchannels) [4]. In a swine model of cardiac
arrest, levosimendan significantly improved the initial
resuscitation success, increased coronary perfusion pres-
sure and elevated regional brain oxygen saturation [5].
Levosimendan favourably affects mitochondrial adeno-
sine triphosphate synthesis, conferring cardioprotection
and possible neuronal protection during ischemic
insults. In a model of spinal cord injury, levosimendan
has been reported to attenuate neurologic motor dys-
function [6]. This finding is supported by the fact that
the selective mitoKATPchannel opener, diazoxide, is an
effective neuroprotectant, as has been demonstrated in
an ischemia reperfusion study in rats [4]. In fact, it has
been observed that the secondary injury following a
traumatic brain injury is similar to the post-ischemic
neuronal damage observed in the penumbra surround-
ing the ischemic core after a stroke [7]. In the present
study, we tested the hypothesis that levosimendan
would provide neuroprotection for these selectively vul-
nerable neurons in an in vitro, organotypic, hippocampal
slice model of cerebral trauma.
Methods
All experiments were performed in compliance with the
local institution’s Ethical Review Committee and were
* Correspondence: aroehl@ukaachen.de
† Contributed equally
1Department of Anaesthesiology, RWTH Aachen University Hospital,
Pauwelsstraße 30, 52074 Aachen, Germany
Full list of author information is available at the end of the article
Roehl et al. BMC Neurology 2010, 10:97
http://www.biomedcentral.com/1471-2377/10/97
© 2010 Roehl et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
approved by an animal protection representative at the
Institute of Animal Research at the RWTH Aachen Uni-
versity Hospital, in accordance with German Animal
Protection aw §4, Section 3. Organotypic hippocampal
slices were prepared as reported previously, using the
brains from six- to eight-day-old C57/BL6 mouse pups
(Charles River Laboratories, Sulzfeld, Germany) [2,8,9].
Unless otherwise stated, all chemicals were obtained
from PAA Laboratories GmbH (Pasching, Austria). The
slices were maintained in culture for 14 days before
experimentation. Traumatic brain injury was produced
using a specially designed apparatus, which was also as
previously reported [8]. Under stereomicroscopic super-
vision, a 1.65-mm diameter stylus was positioned 7 mm
above the CA1 region of the hippocampal slices with
the aid of a three-axis micromanipulator; the stylus was
then dropped onto the slice with constant and reprodu-
cible impact energy of 5.26 μJ. For the experimental
groups, the medium was exchanged immediately after
trauma with an experimental medium containing levosi-
mendan (Simdax®, 2.5 mg/ml, Orion Pharma, Espoo,
Finland) at concentrations of 0.001 μM (n = 41), 0.01
μM (n = 41) and 0.1 μM (n = 52). Injured, untreated
slices were considered the control group (n = 30). The
slices were cultivated for 72 hrs in an incubator with an
atmosphere of 95% air and 5% carbon dioxide at 37°C,
after which cell death was quantified by measuring the
intensity of propidium iodide (PI) fluorescence in the
CA1 area (Figure 1).
Two types of tissue injury were examined: “total
injury” was defined as the complete injury over the slice,
whereas “secondary injury” described the injured area
on the slice that excludes the primary impact site of the
stylus. The relationship between the cumulative fluores-
cence emissions in PI-treated tissues and the number of
damaged cells when compared to cell viability was
assumed to be linear. Tissue injury in the slices was
measured by pixel-based image analysis using ImageJ
software (NIH; USA, http://rsb.info.nih.gov). This
method has been proved effective in several previous
studies [2,8-10]. The fluorescence images were digita-
lised at eight bits, allowing us to classify the images on a
spectrum of 256 (from 0 to 255) greyscale levels.
Damaged regions with high PI uptake emitted fluores-
cence at a high greyscale level, while vital regions
showed only minor emissions. The red channel of each
image was analysed with ImageJ software. For each
image, ImageJ generated a histogram that showed the
absolute number of pixels sharing the same greyscale
value. Histograms from non-traumatised slices showed
that the vast majority of all pixels had greyscale values
between 10 and 100, representing mostly background
fluorescence. In contrast, traumatised slices showed, in
addition to their background fluorescence, a well-
defined peak of values between 160 and 185 (Figure 2).
As in previous publications [2,8,9], we established a
threshold (in this instance, at a greyscale value of 100)
that proved to be valid for distinguishing between trau-
matised and non-traumatised cells. Integrating the area
Figure 1 After preparation, cultivation for 14 days and
baseline measurement, slices were traumatised by dropping of
a stylus onto the CA1 region of the hippocampus. Figure 1a
shows a native hippocampal slice prior to treatment. Figure 1b
shows a non-traumatised, and un-treated negative control slice. The
open circle tags the region of primary impact in Figure 1c and d.
The treatment with 0.1 μM levosimendan (d) reduced visible the
trauma intensity compared with the un-treated control (c).
Figure 2 Cell injury was quantified by measuring propidium
iodide (PI) fluorescence as it entered only cells with damaged
cell membranes. The extent of the trauma was evaluated by
fluorescence imaging 72 hours after trauma was induced, using
pixel-based analysis of the resulting images. The control curve
shows the histogram of un-treated slices (n = 30). The second curve
shows the histogram of traumatised slices treated with 0.1 μM
levosimendan (n = 52). The shaded region around each line
indicates the SD. The extent of the injury was quantified by
integrating the area at the sections where the pixel value fell above
the threshold of 100.
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under the histogram curve for all pixel values exceeding
the threshold then allowed us to quantify cell injury.
To calculate the extent of the secondary injury, ImageJ
was used to create a mask with the same diameter as
the stylus. The mask was positioned directly over the
stylus’ impact site in the images, and that area was then
excluded from the pixel analysis and subsequent calcula-
tions of trauma. The same mask was applied to every
image when calculating the secondary injury. All values
were normalised in reference to the control injury,
which was defined as 100%. Both the mean value and
the standard deviation (SD) were calculated for the
trauma intensities of the slices in each group. One-way
analysis of variance (ANOVA) with Bonferoni post-hoc
analysis was used to test for statistical significance. A
P-value of less than or equal to 0.05 was set as the
threshold for statistical significance (SPSS 17.0, SPSS
Inc., Chicago, IL, USA).
Results and Discussion
We found that levosimendan significantly diminished
both total (p = 0.000) and secondary (p = 0.000) injury
when administered in this in vitro model of traumatic
brain injury. There appeared to be a dose-dependent
neuroprotective effect in the observed range (between
0.001 and 0.1 μM) of levosimendan concentrations.
Total injury in the experimental groups was significantly
reduced relative to the control injury: to 66 ± 7% (p =
0.04) at 0.01 μM and to 42 ± 7% (p = 0.000) at 0.1 μM
levosimendan (Figure 3A). The secondary injury, which
accounted for approximately 66 ± 5% of the total injury,
was reduced to 40 ± 4% (p = 0.009) and 20 ± 5% (p =
0.000) of the total control injury when treated with 0.01
μM and 0.1 μM levosimendan, respectively (Figure 3B).
The reduction observed in the group treated with 0.001
μM levosimendan was not statistically significant for
either total or secondary injury.
The precise mechanisms by which mitoKATPchannel
activation protects the brain are unclear. One possible
explanation is that the acute activation of mitoKATP chan-
nels results in K+ influx, organelle depolarisation, and the
expansion of mitochondrial matrix volume. Mitochondrial
Ca2+ overload has been closely correlated with mitochon-
drial damage, which can result in both necrotic and apop-
totic forms of cell death [4]. Thus, despite the profound
differences in cellular physiology and sensitivity to anoxic
injury that exist between myocardial cells and neurons,
the same pharmacological approach has been shown to
protect the heart [11] and, possibly, the brain, thereby sav-
ing both brain and heart tissues. The occurrence of focal
injury at the primary site of impact and the subsequent
development of secondary injury distant from the site are
also comparable to the in vivo situation. Thus, this model
can be confidently used as the testing environment for
experimental treatments. In fact, we found that the sec-
ondary injury following traumatic brain injury displayed
many similarities to the post-ischemic neuronal damage
that can be observed in the penumbra surrounding the
ischemic core following a stroke [7]. This likeness suggests
that similar neuroprotective strategies may be successful
in both etiologies of brain injury. The nature of the model
excludes mechanisms of injury that are specific to brain
damage in the in vivo situation, such as injury pathways
related to brain swelling inside an enclosed skull, reperfu-
sion injury, global or local ischemia, global or local
hypoxia and other systemic variables [9]. Another limita-
tion of this study is that levosimendan was administered
directly following traumatisation, thus failing to account
for the effects of delayed treatment that may be encoun-
tered in the routine clinical management of patients with
traumatic brain injury, global ischemia or local ischemia.
Conclusions
The present in vitro study demonstrated that levosimen-
dan worked as an effective neuroprotectant in an
in vitro model of traumatic brain injury. Levosimendan
reduced both the total tissue injury and the secondary
injury distant from the primary site of brain injury. The
effects were observed at two different concentrations
(0.01 and 0.1 μM) of levosimendan.
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